Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Clinical trial NCT01836432 · TERMINATED

Trial details

NCT number: NCT01836432
Sponsor: NewLink Genetics Corporation
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Pancreatic Cancer Pancreatic Carcinoma Non-resectable Locally Advanced Malignant Neoplasm

Start date: 2013-05-01
Primary completion: 2016-07-29
Enrollment: 302

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.